Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck

Investigational New Drugs

Volumn 31, Issue 5, 2013, Pages 1207-1216

  Machiels, Jean Pascal ^a   Kaminsky, Marie Christine ^b   Keller, Ulrich ^c   Brümmendorf, Tim H ^d   Goddemeier, Thomas ^e   Forssmann, Ulf ^f   Delord, Jean Pierre ^g  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CENTRE ALEXIS VAUTRIN   (France)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e MERCK KGAA   (Germany)

^f MERCK SERONO S A   (Switzerland)

^g INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

IMO 2055 (EMD 1201081); Squamous cell carcinoma of the head and neck (SCCHN); Toll like receptor 9 (TLR9) agonist, cetuximab, Phase I

Indexed keywords

AGATOLIMOD; CETUXIMAB; CISPLATIN; EMD 1201081; FLUOROURACIL; IMO 2055; UNCLASSIFIED DRUG;

ACNE; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACTEREMIA; CANCER PALLIATIVE THERAPY; CHILL; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; CYSTITIS; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DISTANT METASTASIS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DRY NOSE; DRY SKIN; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLICULITIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTENSION; HYPERTHERMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; IMMUNOGENICITY; INFECTION; INJECTION SITE ERYTHEMA; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYCOSIS; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PARONYCHIA; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QT PROLONGATION; RASH; RECURRENT CANCER; SEPSIS; SEPTICEMIA; SIDE EFFECT; SKIN FISSURE; STOMATITIS; T WAVE INVERSION; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDES; TOLL-LIKE RECEPTOR 9; TREATMENT OUTCOME;

EID: 84884819741     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9933-z     Document Type: Article

References (25)

1. Westra WH (2009) The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer. Head Neck Pathol 3:78-81
2. Worsham MJ (2011) Identifying the risk factors for late-stage head and neck cancer. Expert Rev Anticancer Ther 11:1321-1325
3. Langer CJ (2008) Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer 112:2635-2645
4. Gibson MK, Li Y, Murphy B et al (2005) Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23:3562-3567
5. Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127
6. Grégoire V, Lefebvre J-L, Licitra L, Felip E (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl 5):v184-v186
7. Damiano V, Caputo R, Bianco R et al (2006) Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res 12:577-583
8. Damiano V, Caputo R, Garofalo S et al (2007) TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci USA 104:12468-12473
9. Rosa R, Melisi D, Damiano V et al (2011) Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Clin Cancer Res 17:6531-6541
10. Vicari AP, Luu R, Zhang N et al (2009) Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 58:615-628
11. Zent CS, Smith BJ, Ballas ZK et al (2012) Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma 53:211-217
12. Kim YH, Girardi M, Duvic M et al (2010) Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment- refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 63:975-983
13. Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM (2009) Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer 7:E58-E65
14. Kuzel T, Dutcher J, Ebbinghaus S et al (2009) A phase 2 multicenter, randomized, open-label study of two dose levels of IMO-2055 in patients with metastatic or recurrent renal cell carcinoma. Presented at the 8th International Kidney Cancer Symposium (Sept 25-26): http://www.iderapharma.com/development/ IMO-2055-Poster-2.pdf
15. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U (2008) Phase 1 evaluation of intralesionally injected TLR9-Agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 31:520-527
16. Smith DA, Conkling P, Richards DA et al (2012) Efficacy and safety of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy. J Clin Oncol 30(suppl; abstract e18047)
17. Manegold C, van Zandwijk N, Szczesna A et al (2012) A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 23:72-77
18. Hirsh V, Paz-Ares L, Boyer M et al (2011) Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 29:2667-2674
19. Malik S, Hwang J, Cotarla I et al (2007) Initial phase 1 results of gemcitabine, carboplatin and IMO-2055, a toll like receptor 9 (TLR9) agonist, in patients (pts) with advanced solid tumors: P3-112. J Thorac Oncol 2:S726-S727
20. Storer BE (1989) Design and analysis of phase I clinical trials. Biometrics 45:925-937
21. Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115-124
22. Sánchez-González PD, López-Hernández FJ, López-Novoa JM, Morales AI (2011) An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit Rev Toxicol 41:803-821
23. Stoehlmacher-Williams J, Villanueva C, Foa P et al (2012) Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial. J Clin Oncol 30 (suppl; abstract 5504)
24. Vermorken JB, Stöhlmacher J, Davidenko I et al (2009) An analysis of safety in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving chemotherapy (CT) with or without panitumumab (pmab) in a phase III clinical trial (SPECTRUM). J Clin Oncol 27:15 s(suppl; abstract 6050)
25. Vermorken JB, Guigay J, Mesia R et al (2011) Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer 104:1691-1696